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1. INTRODUCTION {#cam42823-sec-0005}
===============

Primary liver cancer is the sixth most common cancer and the fourth leading cause of cancer‐related mortality worldwide, which consists of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and mixed hepatocellular‐cholangiocarcinoma carcinoma.[1](#cam42823-bib-0001){ref-type="ref"} Though originating from different cell origins, HCC and ICC frequently share several common etiological risk factors and clinical manifestations, which is a challenge in differential diagnosis between HCC and ICC.[2](#cam42823-bib-0002){ref-type="ref"}, [3](#cam42823-bib-0003){ref-type="ref"}, [4](#cam42823-bib-0004){ref-type="ref"} Because HCC and ICC differ in therapeutic strategies and prognosis, preoperative accurate differentiation and early diagnosis are necessary to improve the treatment outcome.[5](#cam42823-bib-0005){ref-type="ref"}, [6](#cam42823-bib-0006){ref-type="ref"}, [7](#cam42823-bib-0007){ref-type="ref"} However, in current clinical practice, the gold standard of differential diagnosis still depends on the pathological examination after liver resection.[8](#cam42823-bib-0008){ref-type="ref"} Therefore, an accurate preoperative differentiation is of great significance in clinical decision‐making.

Many efforts on preoperative differential diagnosis have been made in recent years. Magnetic resonance imaging (MRI) and contrast‐enhanced computerized tomography (CT) are most applied to discriminate the two subtypes, but hardly to differentiate small ICC from HCC in cirrhotic livers due to their common enhancement patterns.[9](#cam42823-bib-0009){ref-type="ref"}, [10](#cam42823-bib-0010){ref-type="ref"}, [11](#cam42823-bib-0011){ref-type="ref"}, [12](#cam42823-bib-0012){ref-type="ref"}, [13](#cam42823-bib-0013){ref-type="ref"}, [14](#cam42823-bib-0014){ref-type="ref"} Of contrast‐enhanced ultrasound (US), the risk of misdiagnosis of ICC for HCC is also not negligible.[15](#cam42823-bib-0015){ref-type="ref"}, [16](#cam42823-bib-0016){ref-type="ref"} Besides, alpha‐fetoprotein (AFP) and carbohydrate antigen 19‐9 (CA199) are regarded as optimal serum biomarkers to distinguish HCC from ICC while the diagnostic sensitivity and specificity of these biomarkers are unsatisfactory.[7](#cam42823-bib-0007){ref-type="ref"}, [17](#cam42823-bib-0017){ref-type="ref"}, [18](#cam42823-bib-0018){ref-type="ref"} Thus, better preoperative prediction models are needed to differentiate HCC from ICC.

Serum inflammatory indices are reflective of the systematic inflammation, which play an essential role in cancer development and progression.[19](#cam42823-bib-0019){ref-type="ref"} Inflammatory indices have shown to be prognostic in primary liver cancer including the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), lymphocyte‐to‐monocyte ratio (LMR), aspartate aminotransferase‐to‐platelet ratio index (APRI) and aspartate aminotransferase‐to‐neutrophil ratio index (ANRI).[20](#cam42823-bib-0020){ref-type="ref"}, [21](#cam42823-bib-0021){ref-type="ref"}, [22](#cam42823-bib-0022){ref-type="ref"}, [23](#cam42823-bib-0023){ref-type="ref"}, [24](#cam42823-bib-0024){ref-type="ref"}, [25](#cam42823-bib-0025){ref-type="ref"} What is more, inflammatory indices were used to differentiate the existence of microvascular invasion in HCC.[26](#cam42823-bib-0026){ref-type="ref"} Whether inflammatory indices could be used to distinguish HCC from ICC has never been explored. The objective of our study was to develop a nomogram based on inflammatory indices for the preoperative differential diagnosis between ICC and HCC.

2. METHODS {#cam42823-sec-0006}
==========

2.1. Patients {#cam42823-sec-0007}
-------------

With the approval of the Xiangya Hospital of Central South University, a retrospective study was conducted on a training cohort of HCC and ICC patients who underwent partial hepatectomy between January 2014 and December 2018. The study was conducted in compliance with the Declaration of Helsinki and written informed consent was obtained from all patients for their data to be used for research. Patients did not receive financial compensation. The inclusion criteria were as follows: (a) patients were above 18 years old; (b) underwent surgical resection; (c) pathological diagnosis of HCC and ICC. Diagnostic criteria were based on Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition); (d) imaging data and serum inflammatory data were available before surgery. The exclusion criteria were as follows: (a) patients were less than 18 years old; (b) patients were diagnosed as metastatic tumor before; (c) patients had infection before surgery; (d) imaging data and serum inflammatory data were incomplete or unavailable. From January 2019 to November 2019, using the same inclusion and exclusion criteria, an independent cohort of consecutive HCC and ICC patients who underwent partial hepatectomy was prospectively studied. These patients constituted the validation cohort of the study.

2.2. Clinicopathologic variables {#cam42823-sec-0008}
--------------------------------

Patients' demographic variables were obtained including age, sex, body mass index, history of diabetes, hypertension, and hepatitis. Number of tumor nodules, tumor size and ascites were included in patients' imaging data based on contrast‐enhanced MRI and contrast‐enhanced CT. Serum examination included indocyanine green retention rate at 15 minutes (ICG‐R15), AFP, carcinoembryonic antigen (CEA), CA199, albumin (ALB), total bilirubin (TBIL), direct bilirubin (DBIL), alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), prothrombin time (PT), international normalized ratio (INR), neutrophil, lymphocyte, monocyte, platelet, hemoglobin, NLR, PLR, LMR, APRI, and ANRI. In our study, NLR was measured by the neutrophils count divided by the lymphocytes count; PLR was measured by the platelet count divided by the lymphocyte count; LMR was measured by the lymphocytes count divided by the monocytes count. APRI was obtained using the following formula: APRI = \[AST level (/ULN)/Platelet counts (10^9^/L)\] × 100. ANRI was calculated by AST divided by the neutrophils count.

2.3. Statistical analysis {#cam42823-sec-0009}
-------------------------

Continuous variables were expressed as mean ± SD and Student\'s *t* test was used for the comparison. Categorical variables were expressed as frequency and compared using Fisher exact test. Multivariate logistic regression analysis was used to identify the independent ICC differential factors. Nomogram was plotted based on these independent differential factors. Receiver operating characteristic (ROC) curve analysis was used for comparison between our nomogram and other models based on the concordance index (C index). A calibration curve with 422 bootstrap samples was employed to measure the accuracy of the nomogram. For the external validation of the nomogram, the established nomogram was used to calculate the total points of each patient in the validation cohort, and ROC curve and calibration curve were plotted to assess the accuracy of the nomogram. The decision curve analysis (DCA) was conducted to evaluate the clinical utility of the nomogram and other models through quantifying net benefits against a range of threshold probabilities. SPSS 22.0 (SPSS Inc, Chicago, IL, USA), EmpowerStats, State SE and R 3.1.2 software (Institute for Statistics and Mathematics) were performed in our analysis. *P* \< .05 was considered statistically significant.

3. RESULTS {#cam42823-sec-0010}
==========

3.1. Clinicopathologic Characteristics of Patients {#cam42823-sec-0011}
--------------------------------------------------

During the study period, 520 consecutive patients who met the inclusion criteria were enrolled, and divided into training cohort and validation cohort. In the training cohort, a total of 422 primary live cancer patients were enrolled into this study, including 375 HCC patients and 47 ICC patients. For the validation cohort, 98 consecutive patients were studied, consisting of 88 HCC patients and 10 ICC patients. The clinicopathologic characteristics of the patients are listed in Table [1](#cam42823-tbl-0001){ref-type="table"}. The baseline clinicopathologic data were comparable between the training and validation cohorts.

###### 

Characteristics of patients in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC)

  Variables                  Training (n = 422)   Validation (n = 98)   *P* value
  -------------------------- -------------------- --------------------- -----------
  Demographics and history                                              
  Age (years)                52.71 ± 11.37        54.17 ± 12.66         .264
  Sex                                                                   
  Man                        358                  84                    .826
  Woman                      64                   14                     
  BMI                        23.03 ± 3.20         23.40 ± 2.88          .323
  Diabetes                                                              
  No                         392                  87                    .173
  Yes                        30                   11                     
  Hypertension                                                          
  No                         343                  84                    .302
  Yes                        79                   14                     
  Etiology                                                              
  Hepatitis                  341                  79                    .965
  Others                     81                   19                     
  Tumor type                                                            
  HCC                        375                  88                    .790
  ICC                        47                   10                     
  Preoperative blood tests                                              
  ICG‐R15 (%)                5.97 ± 6.22          8.34 ± 8.97           .055
  AFP (ng/mL)                288.47 ± 428.09      326.08 ± 381.44       .4251
  CEA (ng/mL)                3.42 ± 8.86          5.84 ± 37.52          .526
  CA199 (ng/mL)              50.87 ± 129.87       33.55 ± 103.53        .2181
  ALB (g/L)                  41.07 ± 4.53         40.54 ± 4.43          .300
  TBIL (μmol/L)              15.02 ± 13.78        13.52 ± 6.78          .295
  DBIL (μmol/L)              6.92 ± 8.18          7.02 ± 3.58           .905
  ALT (U/L)                  44.01 ± 40.57        45.89 ± 64.17         .782
  AST (U/L)                  49.64 ± 45.12        45.96 ± 37.17         .453
  PT (s)                     13.88 ± 5.89         13.78 ± 1.55          .862
  INR                        1.07 ± 0.10          1.08 ± 0.13           .4241
  Neutrophil (10^9^/L)       3.64 ± 2.36          3.38 ± 1.49           .293
  Lymphocyte (10^9^/L)       1.53 ± 0.97          1.39 ± 0.55           .159
  Monocyte (10^9^/L)         0.81 ± 1.67          0.73 ± 0.72           .650
  Platelet (10^9^/L)         163.76 ± 76.05       161.35 ± 80.96        .7801
  HB (g/L)                   142.21 ± 67.00       138.68 ± 16.53        .606
  NLR                        2.76 ± 2.19          2.83 ± 2.21           .758
  PLR                        121.97 ± 73.45       50.94 ± 21.24         \<.001
  LMR                        3.34 ± 1.79          3.21 ± 1.33           .482
  APRI                       1.17 ± 5.34          0.91 ± 1.06           .626
  ANRI                       16.74 ± 17.69        15.04 ± 10.16         .361
  Preoperative imaging                                                  
  Tumor number                                                           
  Solitary                   362                  79                    .199
  Multiple                   60                   19                     
  Tumor size (cm)            6.42 ± 4.61          6.30 ± 3.85           .818
  Ascites                                                               
  No                         411                  94                    .432
  Yes                        11                   4                      

Categorical variables are expressed as frequency. Continuous variables are expressed as mean ± standard deviation.

Abbreviations: AFP, α‐fetoprotein level; ALB, albumin; ALT, alanine transaminase; ANRI, AST‐to‐neutrophil ratio index; APRI, AST‐to‐platelet ratio index; AST, aspartate transaminase; CA199, cancer antigen 199; CEA, carcinoembryonic antigen; DBIL, direct bilirubin; ICG‐R15, indocyanine green retention rate at 15 min; INR, international normalized ratio; LMR, lymphocyte‐to‐monocyte ratio; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‐to‐lymphocyte ratio; PT, prothrombin time; PTA, prothrombin activity; TBIL, total bilirubin.
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3.2. Univariate and multivariate analysis of differential factors between ICC and HCC {#cam42823-sec-0012}
-------------------------------------------------------------------------------------

In the training cohort, the univariate analysis suggested that age (*P* = .033), sex (*P* \< .001), hepatitis (*P* \< .001), AFP (*P* \< .001), CA199 (*P* \< .001), INR (*P* \< .001), Neutrophil (*P* \< .001), Platelet (*P* \< .001), NLR (*P* = .018), PLR (*P* \< .001), LMR (*P* = .023), and ANRI (*P* \< .001) were potential differential factors between ICC and HCC (Table [2](#cam42823-tbl-0002){ref-type="table"}). Subsequently, all these potential differential factors were recruited into multivariate logistic analysis. Only sex (OR = 9.001, 95% CI: 3.268 ‐ 24.792, *P* \< .001), hepatitis (OR = 0.323, 95% CI: 0.121‐0.860, *P* = .024), AFP (OR = 0.997, 95% CI: 0.995‐1.000, *P* = .046), CA199 (OR = 1.016, 95% CI: 1.007‐1.025, *P* \< .001) and ANRI (OR = 0.904, 95% CI: 0.843‐0.969, *P* = .004) were the independent differential factors for the presence of ICC (Figure [1](#cam42823-fig-0001){ref-type="fig"}).

###### 

Characteristics of patients in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC)

  Variables                  HCC (n = 375)     ICC (n = 47)      *P* value
  -------------------------- ----------------- ----------------- ------------
  Demographics and history                                       
  Age (years)                52.29 ± 11.44     56.04 ± 10.35     **.033**
  Sex                                                            
  Man                        331               27                **\<.001**
  Woman                      44                20                 
  BMI                        23.03 ± 3.22      23.04 ± 3.08      .985
  Diabetes                                                       
  No                         347               45                .558
  Yes                        28                2                  
  Hypertension                                                   
  No                         304               39                .845
  Yes                        71                8                  
  Etiology                                                       
  Hepatitis                  327               14                **\<.001**
  Others                     48                33                 
  Preoperative blood tests                                       
  ICG‐R15 (%)                6.16 ± 6.52       4.69 ± 3.49       .213
  AFP (ng/mL)                320.05 ± 439.77   36.46 ± 178.37    **\<.001**
  CEA (ng/mL)                2.79 ± 4.19       8.34 ± 23.20      .108
  CA199 (ng/mL)              26.79 ± 28.16     242.98 ± 324.79   **\<.001**
  ALB (g/L)                  40.99 ± 4.53      41.71 ± 4.58      .310
  TBIL (μmol/L)              14.62 ± 10.64     18.25 ± 28.36     .389
  DBIL (μmol/L)              6.78 ± 7.26       8.03 ± 13.55      .538
  ALT (U/L)                  44.01 ± 40.55     44.02 ± 41.19     .999
  AST (U/L)                  50.68 ± 46.70     41.31 ± 28.67     .180
  PT (s)                     13.99 ± 6.23      13.01 ± 0.84      .284
  INR                        1.07 ± 0.10       1.02 ± 0.07       **\<.001**
  Neutrophil (10^9^/L)       3.47 ± 2.32       5.01 ± 2.29       **\<.001**
  Lymphocyte (10^9^/L)       1.54 ± 1.01       1.46 ± 0.62       .588
  Monocyte (10^9^/L)         0.82 ± 1.74       0.75 ± 1.01       .791
  Platelet (10^9^/L)         156.90 ± 74.21    218.55 ± 68.55    **\<.001**
  HB (g/L)                   143.37 ± 70.76    132.98 ± 17.00    .371
  NLR                        2.59 ± 1.70       4.13 ± 4.25       **.018**
  PLR                        116.07 ± 70.77    169.00 ± 78.17    **\<.001**
  LMR                        3.41 ± 1.82       2.78 ± 1.47       **.023**
  APRI                       1.26 ± 5.66       0.51 ± 0.35       .356
  ANRI                       17.68 ± 18.41     9.24 ± 6.53       **\<.001**
  Preoperative imaging                                           
  Tumor number                                                   
  Solitary                   320               42                .657
  Multiple                   55                5                  
  Tumor size (cm)            6.35 ± 4.79       7.00 ± 2.78       .364
  Ascites                                                        
  No                         346               47                .620
  Yes                        11                0                  

Categorical variables are expressed as frequency. Continuous variables are expressed as mean ± standard deviation.

ICG‐R15, indocyanine green retention rate at 15 min.

Abbreviations: AFP, α‐fetoprotein level; ALB, albumin; ALT, alanine transaminase; ANRI, AST‐to‐neutrophil ratio index; APRI, AST‐to‐platelet ratio index; AST, aspartate transaminase; CA199, cancer antigen 199; CEA, carcinoembryonic antigen; DBIL, direct bilirubin; INR, international normalized ratio; LMR, lymphocyte‐to‐monocyte ratio; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‐to‐lymphocyte ratio; PT, prothrombin time; PTA, prothrombin activity; TBIL, total bilirubin.

Bold indicates statistically significant values (*P* \< .05).
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![Plot of independent differential factors between intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) based on multivariate logistic regression analysis](CAM4-9-1451-g001){#cam42823-fig-0001}

3.3. Development and validation of a nomogram for ICC differential diagnosis {#cam42823-sec-0013}
----------------------------------------------------------------------------

The independent differential factors between ICC and HCC were further employed to establish an ICC risk estimation nomogram (Figure [2](#cam42823-fig-0002){ref-type="fig"}). To highlight the significance of ANRI, we built model 1 including gender, hepatitis, AFP, and CA199. Also, we established model 2 enrolling AFP and CA199, which was mostly used in clinic practice. Comparing with model 1 (C index = 0.903, 95% CI: 0.849‐0.957) and model 2 (C index = 0.850, 95% CI: 0.791‐0.908), the nomogram showed a better discrimination for ICC and HCC with an C index of 0.920 (95% CI, 0.872‐0.968) (Figure [3](#cam42823-fig-0003){ref-type="fig"}). The calibration curves revealed sufficient agreement between the nomogram and actual histopathologic confirmation on surgical specimens (Figure [4](#cam42823-fig-0004){ref-type="fig"}). In the validation cohort, comparing with model 1 (C index = 0.925, 95% CI: 0.842‐1.000) and model 2 (C index = 0.865, 95% CI: 0.772‐0.957), the nomogram displayed a C index of 0.967 (95% CI, 0.925‐1.000) for the differentiation of ICC risk (Figure [5](#cam42823-fig-0005){ref-type="fig"}). There was also a good calibration curve for the ICC risk estimation (Figure [6](#cam42823-fig-0006){ref-type="fig"}). DCA has been used to assess the clinical value of models which integrates the preferences of patients into the analysis.[27](#cam42823-bib-0027){ref-type="ref"}, [28](#cam42823-bib-0028){ref-type="ref"} DCA showed that using this nomogram to distinguish ICC from HCC added more benefit compared with model 1 and 2 (Figure [7](#cam42823-fig-0007){ref-type="fig"}).

![Nomogram for differentiating ICC and HCC](CAM4-9-1451-g002){#cam42823-fig-0002}

![Receiver operating characteristic (ROC) curve of the nomogram and other models in the training cohort. Model 1 consists of sex, hepatitis, alpha‐fetoprotein (AFP), and carbohydrate antigen 19‐9 (CA199); model 2 includes AFP and CA199](CAM4-9-1451-g003){#cam42823-fig-0003}

![Calibration curve of the nomogram in the training cohort](CAM4-9-1451-g004){#cam42823-fig-0004}

![Receiver operating characteristic (ROC) curve of the nomogram and other models in the validation cohort](CAM4-9-1451-g005){#cam42823-fig-0005}

![Calibration curve of the nomogram in the validation cohort](CAM4-9-1451-g006){#cam42823-fig-0006}

![Decision curve analysis of our nomogram and other models](CAM4-9-1451-g007){#cam42823-fig-0007}

3.4. Risk of ICC based on the nomogram scores {#cam42823-sec-0014}
---------------------------------------------

Sensitivity and specificity for the ICC differential nomogram at different predicted probabilities were summarized in Table [3](#cam42823-tbl-0003){ref-type="table"}. Based on the maximum of the Youden index, the optimal cutoff for the nomogram predicted probability were set to be 0.088. The sensitivity, specificity, positive predictive value, and negative predictive value when used in differentiating ICC from HCC were 85.11%, 86.13%, 43.48%, and 97.88%, respectively (Table [4](#cam42823-tbl-0004){ref-type="table"}).

###### 

Differential efficacy of the nomogram at different predicted probability

  Predicted probability   Sensitivity   Specificity   PPV      NPV
  ----------------------- ------------- ------------- -------- --------
  0.01                    97.87%        32.53%        15.38%   99.19%
  0.05                    89.36%        74.93%        30.88%   98.25%
  0.10                    80.85%        86.40%        42.70%   97.30%
  0.20                    70.21%        93.60%        57.89%   96.16%
  0.30                    65.96%        97.60%        77.50%   95.81%
  0.40                    61.70%        98.13%        80.56%   95.33%

Abbreviations: NPV, negative predictive value; PPV, positive predictive value.
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###### 

Differential efficacy of the nomogram at optimal predicted probability

  Variables                   Value
  --------------------------- ------------------
  Sensitivity                 85.11%
  Specificity                 86.13%
  Positive predictive value   43.48%
  Negative predictive value   97.88%
  Positive likelihood ratio   6.14
  Negative likelihood ratio   0.17
  ROC area (95%CI)            0.92 (0.87‐0.97)
  Predicted probability       0.088

Abbreviations: CI, confidence intervals; ROC, receiver operating characteristic.
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4. DISCUSSION {#cam42823-sec-0015}
=============

Many models have been put forward to distinguish ICC from HCC based on MRI, CT, and US, but their value of clinical use is limited due to the lack of costly high‐resolution equipment and experienced radiologists especially in some developing areas.[5](#cam42823-bib-0005){ref-type="ref"}, [10](#cam42823-bib-0010){ref-type="ref"}, [11](#cam42823-bib-0011){ref-type="ref"}, [12](#cam42823-bib-0012){ref-type="ref"}, [13](#cam42823-bib-0013){ref-type="ref"}, [16](#cam42823-bib-0016){ref-type="ref"} Besides, considering that many high‐risk patients are ineligible for the application of MRI and CT, we aim to establish a simple but accurate differential diagnosis model for differentiating ICC from HCC for clinical use.

In our study, we found that sex, hepatitis, AFP, CA199, and ANRI were the independent differential factors between ICC and HCC through the multivariable logistic regression analysis. Based on these independent differential factors, we established a nomogram to distinguish ICC from HCC. Hepatitis, AFP, and ANRI were negatively related to ICC, while female and CA199 were positive factors in this ICC differential nomogram. Hepatitis is the main risk factor of HCC and AFP is secreted by about half of the HCC tumor.[29](#cam42823-bib-0029){ref-type="ref"}, [30](#cam42823-bib-0030){ref-type="ref"} Though AFP was not recommended for the HCC diagnosis by the "American Association for the Study of Liver Disease" (AASLD) and the "European Association for Study of the Liver" (EASL), AFP is still a part of the diagnostic criteria of HCC in Asian countries.[31](#cam42823-bib-0031){ref-type="ref"}, [32](#cam42823-bib-0032){ref-type="ref"} Epidemiological studies have shown a higher incidence of HCC in men than in women. A possible reason is that higher adiponectin in women could activate AMPKα and p38α which confers protection against HCC.[33](#cam42823-bib-0033){ref-type="ref"} Admittedly, hepatitis, AFP, sex, and CA199 have been demonstrated to distinguish ICC from HCC in many studies which are consistent with our conclusion, while lower ANRI in ICC than in HCC has never been investigated.[7](#cam42823-bib-0007){ref-type="ref"}, [17](#cam42823-bib-0017){ref-type="ref"}, [18](#cam42823-bib-0018){ref-type="ref"} In our case, AST in ICC patients is lower than in HCC patients because HCC patients usually are infected with hepatitis virus which was correlated with the AST level.[34](#cam42823-bib-0034){ref-type="ref"} Furthermore, more neutrophils are recruited by ICC cells through expressing chemokine ligand 5.[35](#cam42823-bib-0035){ref-type="ref"} ANRI, a ratio of AST divided by neutrophils count, amplifies the effects of AST and neutrophil in differential diagnosis between ICC and HCC, which could reflect the hepatocyte injury and the tumor burden and progression.[20](#cam42823-bib-0020){ref-type="ref"} That may also explain why ANRI not other inflammatory indices could be used to differentiate ICC from HCC.

In current clinical practice, clinicians usually employ AFP and CA199 to distinguish ICC and HCC.[7](#cam42823-bib-0007){ref-type="ref"}, [17](#cam42823-bib-0017){ref-type="ref"}, [18](#cam42823-bib-0018){ref-type="ref"} Compared to our nomogram (C‐index = 0.920), this model (model 2) has a lower C‐index value of 0.850. To highlight the significance of ANRI, we established model 2 which consists of sex, hepatitis, AFP, and CA199. Compared to model 1 (C‐index = 0.903), our nomogram performs well in differentiating ICC from HCC. Thereafter we used the consecutive patients from our hospital to test the accuracy of our model. The nomogram was validated by the C‐index value of 0.967 in validation cohorts. Conventionally, nomogram is evaluated using sensitivity, specificity, and C‐index which failed to assess the clinical value. DCA is a well‐established method to assess the benefits of a diagnostic test across a range of patient preference for accepting risk of undertreatment and overtreatment to facilitate decisions about test selection and use.[27](#cam42823-bib-0027){ref-type="ref"}, [28](#cam42823-bib-0028){ref-type="ref"} In our case, more benefits were added using our nomogram than other models, suggesting that using our nomogram to differentiate ICC from HCC would be the best decision for all patients, regardless of individual values, and a clinician can use this approach uniformly.

Our nomogram is helpful in the differential diagnosis between ICC and HCC preoperatively, which can guide on therapeutic treatment. For example, HCC patients have multiple curative intent options while surgical resection is the only curative therapy for ICC patients.[36](#cam42823-bib-0036){ref-type="ref"} Unresectable HCC patients could receive liver transplantation while the indication of liver transplantation for ICC remains less defined because of concerns of poor prognosis.[37](#cam42823-bib-0037){ref-type="ref"}, [38](#cam42823-bib-0038){ref-type="ref"} With our nomogram, we can pick up the HCC patients who were misdiagnosed as ICC before. These patients could regain the chance of liver transplantation or other curative treatments. Also, our nomogram may serve as a selection tool during randomized clinical trials on neoadjuvant treatment for recruiting ICC patients.

To our knowledge, this is the first nomogram based on inflammatory indices to differentiate ICC from HCC. We highlight the importance of ANRI in the differential diagnosis between ICC and HCC. However, our study has some limitations. First, this analysis was a retrospective study based on data from a single hospital. Second, an external validation is necessary to confirm the differential value of the nomogram. Finally, due to analysis based on clinicopathologic and serum data, specific markers such as PTTG and microRNA‐204, might further improve the accuracy of the nomogram.[39](#cam42823-bib-0039){ref-type="ref"}, [40](#cam42823-bib-0040){ref-type="ref"}, [41](#cam42823-bib-0041){ref-type="ref"}, [42](#cam42823-bib-0042){ref-type="ref"}, [43](#cam42823-bib-0043){ref-type="ref"}

In conclusion, we demonstrated that sex, hepatitis, AFP, CA199, and ANRI are the independent differential factors between ICC and HCC. By combining these easily accessible differential factors, a differential diagnostic nomogram was established for optimal discrimination between ICC and HCC. The nomogram could optimally differentiate ICC from HCC preoperatively and help with therapeutic options and prognosis evaluation.
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